Inhibition of the protease activity of the light chain of type A botulinum neurotoxin by aqueous extract from stinging nettle (Urtica dioica) leaf

Basic and Clinical Pharmacology and Toxicology

Volumn 95, Issue 5, 2004, Pages 215-219

  Gul, Nizamettin ^a   Ahmed, S Ashraf ^a   Smith, Leonard A ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2 HYDROXYETHYL) 1 PIPERAZINEETHANESULFONIC ACID; ACETYLCHOLINE; BOTULINUM TOXIN A; BOTULINUM TOXIN B; NEUROTOXIN; PROTEINASE; SNARE PROTEIN; SYNAPTOBREVIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; URTICA DIOICA EXTRACT;

ACETYLCHOLINE RELEASE; ARTICLE; CLOSTRIDIUM BOTULINUM; ENZYMATIC ASSAY; ENZYME INHIBITION; ENZYME KINETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IC 50; NONHUMAN; PARALYSIS; PLANT LEAF; PRIORITY JOURNAL; PROTEIN DEGRADATION; URTICA DIOICA;

BOTULINUM TOXIN TYPE A; PEPTIDE HYDROLASES; PLANT EXTRACTS; PLANT LEAVES; PROTEASE INHIBITORS; URTICA DIOICA;

CLOSTRIDIUM BOTULINUM; URTICA; URTICA DIOICA;

EID: 9444236182     PISSN: 17427835     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2004.pto950503.x     Document Type: Article

References (37)

1. Binz, T., J. Blasi, S. Yamasaki, A. Baumeister, E. Link, T. C. Sudhof, R. Jahn & H. Niemann: Proteolysis of SNAP-25 by types E and A botulinal neurotoxins. J. Biol. Chem. 1994, 269, 1617-1620.
2. Black, J. D. & J. O. Dolly. Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis. J. Cell. Biol. 1986, 103, 535-544.
3. Blasi, J., E. R. Chapman, E. Link, T. Binz, S. Yamasaki, P. De Camilli, T. C. Südhof, H. Niemann & R. Jahn: Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 1993a, 365, 160-163.
4. Blasi, J., E. R. Chapman, E. Link, S. Yamasaki, T. Binz, H. Niemann & R. Jahn: Botulinum neurotoxin C1 blocks neurotransmitter release by means of cleaving HPC-1/syntaxin. EMBO J. 1993b, 12, 4821-4828.
5. Burnett, J. C., J. J. Schmidt, R. G. Stafford, R. G. Panchal, T. L. Nguyen, A. R. Hermone, J. L. Vennerstrom, C. F. McGrath, D. J. Lane, E. A. Sausville, D. W. Zaharevitz, R. Gussio & S. Bavari: Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity. Biochem. Biophys. Res. Commun. 2003, 310, 84-93.
6. Chrubasik, S., W. Enderlein, R. Bauer & W. Grabner: Evidence for antirheumatic effectiveness of herba Urticae dioica in acute arthritis: a pilot study. Phytomedicine 1997, 4, 105-108.
7. Cragg, G. M. & D. J. Newman: Medicinals for the millennia: the historical record. Ann. N. Y. Acad Sci. 2001, 953, 3-25.
8. DasGupta, B. R.: The structure of botulinum neurotoxins. In: Botulinum neurotoxin and tetanus toxin. Ed.: L. L. Simpson. Academic Press, San Diego, 1989, pp. 53-67.
9. Garcia, G. E., D. R. Moorad & R. K. Gordon: Buforin I, a natural peptide, inhibits botulinum neurotoxin B activity in vitro. J. Appl. Toxicol. 1999, 19, (Suppl. 1), S19-22.
10. Jensen, M. J., T. J. Smith, S. A. Ahmed, & L. A. Smith: Expression, purification, and efficacy of the type A botulinum neurotoxin catalytic domain fused to two translocation domain variants. Toxicon 2003, 41, 691-701.
11. Kelly, G.: Urtica dioica (stinging nettle): a plant with a "super lectin". North American Pharmacal Inc. 2001, available at http://www.dadamo.com/napharm/store3/template2/uda.htm
12. Kosmeder, J. W. & J. M. Pezzuto: Novel plant-derived anticarcinogens. IARC Sci. Publ. 2002, 156, 343-347.
13. Lacy, D. B., W. Tepp, A. C. Cohen, B. R. DasGupta & R. C. Stevens: Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. 1998, 5, 898-902.
14. Lalli, G., J. Herreros, S. L. Osborne, C. Montecucco, O. Rossetto & G. Schiavo: Functional characterisation of tetanus and botulinum neurotoxins binding domains. J. Cell. Sci. 1999, 112, 2715-2724.
15. Lamanna, C.: The most poisonous poison. Science 1959, 130, 763-765.
16. Mantle, D., T. W. Lennard & A. T. Pickering: Therapeutic applications of medicinal plants in the treatment of breast cancer: a review of their pharmacology, efficacy and tolerability. Adverse Drug React. Toxicol. Rev. 2000, 19, 223-240.
17. Randall, C., K. Meethan, H. Randall & F. Dobbs: Urtica dioica for joint pain-an exploratory study of this complementary therapy. Complement. Ther. Med. 1999, 7, 126-131.
18. Sathyamoorthy, V. & B. R. DasGupta: Separation, purification, partial characterization and comparison of the heavy and light chains of botulinum neurotoxin types A, B, and E. J. Biol. Chem. 1985, 260, 10461-10466.
19. Satoh, E., T. Ishii, Y. Shimizu, S. Sawamura & M. Nishimura: Black tea extract, thearubigin fraction, counteract the effects of botulinum neurotoxins in mice. J. Pharmacol. 2001, 132, 797-798.
20. Schiavo, G., O. Rossetto, F. Tonello & C. Montecucco: Intracellular targets and metalloprotease activity of tetanus and botulinum neurotoxins. In: Clostridial neurotoxins. Ed.: C. Montecucco. Springer, New York, 1995, pp. 257-273.
21. Schiavo, G., O. Rossetto, A. Santucci, B. R. DasGupta & C. Montecucco: Botulinum neurotoxins are zinc proteins. J. Biol. Chem. 1992, 267, 23479-23483.
22. Schiavo, G., O. Rossetto, S. Catsicas, P. P. de Laureto, B. R. Das-Gupta, F. Benfenati & C. Montecucco: Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E. J. Biol. Chem. 1993a, 268, 23784-23787.
23. Schiavo, G., C. C. Shone, O. Rossetto, F. C. Alexander & C. Montecucco: Botulinum neurotoxin serotype F is a zinc endopeptidase specific for VAMP/synaptobrevin. J. Biol. Chem. 1993b, 268, 11516-11519.
24. Schiavo, G., C. Malizio, W. S. Trimble, P. P. de Laureto, G. Milan, H. Sugiyama, E. A. Johnson & C. Montecucco: Botulinum G neurotoxin cleaves VAMP/synaptobrevin at a single Ala-Ala peptide bond. J. Biol. Chem. 1994, 269, 20213-20216.
25. Schmidt, J. J. & R. G. Stafford: A high-affinity competitive inhibitor of type A botulinum neurotoxin protease activity. FEBS Lett. 2002, 532, 423-426.
26. Schmidt, J. J., R. G. Stafford & K. A. Bostian: Type A botulinum neurotoxin proteolytic activity: development of competitive inhibitors and implications for substrate specificity at the S1′ binding subsite. FEBS Lett. 1998, 435, 61-64.
27. Schmidt, J. J. & R. G. Stafford: Fluorigenic substrates for the protease activities of botulinum neurotoxins, serotypes A, B, and F. Appl. Environ. Microbiol. 2003, 69, 297-303.
28. Schmidt, J. J. & K. A. Bostian: Proteolysis of synthetic peptides by type A botulinum neurotoxin. J. Protein Chem. 1995, 14, 703-708.
29. Schmidt, J. J. & K. A. Bostian: Endoproteinase activity of type A botulinum neurotoxin: substrate requirements and activation by serum albumin. J. Protein Chem. 1997, 16, 19-26.
30. Shapiro, R. L., C. Hatheway & D. L. Swerdlow: Botulism in the United States: a clinical and epidemiologic review. Ann. Intern. Med. 1998, 129, 221-228.
31. Shone, C. C., C. P. Quinn, R. Wait., B. Hallis, S. C. Fooks & P. Hambleton: Proteolytic cleavage of synthetic fragments of vesicle-associated membrane protein, isoform-2 by botulinum type B neurotoxin. Eur. J. Biochem. 1993, 217, 965-971.
32. Shone, C. C. & A. Roberts: Peptide substrate specificity and properties of the zinc-endopeptidase activity of botulinum type B neurotoxin. Eur. J. Biochem. 1994, 225, 263-270.
33. Simpson, L. L.: Molecular pharmacology of botulinum toxin and tetanus toxin. Ann. Rev. Pharmacol. Toxicol. 1986, 26, 427-453.
34. Singh, B. R.: Critical aspects of bacterial toxins. In: Natural toxin II: structure, mechanism of action and detection. Eds.: B. R. Singh & A. Tu. Plenum Press, New York, 1996, pp. 63-84.
35. Swaminathan, S. & S. Eswaramoorthy: Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat. Struct. Biol. 2000, 7, 693-699.
36. Yamasaki, S., A. Baumeister, T. Binz, J. Blasi, E. Link, F. Cornille, B. Roques, E. M. Fykse, T. C. Sudhof & R. Jahn: Cleavage of members of the synaptobrevin/VAMP family by types D and F botulinal neurotoxins and tetanus toxin. J. Biol. Chem. 1994, 269, 12764-12772.
37. Yowler, B. C., R. D. Kensinger & C.-L. Schengrund: Botulinum neurotoxin A activity is dependent upon the presence of specific gangliosides in neuroblastoma cells expressing synaptotagmin I. J. Biol. Chem. 2002, 277, 32815-32819.